New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 10, 2014
08:25 EDTBSX, BSX, COV, COV, MDT, MDT, STJ, STJLeerink's medical devices analyst holds an analyst/industry conference call
Medical Devices Analyst Antalffy, along with MEDACorp Specialist George Bakris, MD, discusses a SYMPLICITY HTN-3 principal investigator's outlook on the future of the Renal Denervation Market on an Analyst/Industry conference call. Relevant covered companies BSX, COV, MDT and STJ may be discussed on the Analyst/Industry conference call being held on January 10 at 9 am.
News For BSX;COV;MDT;STJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 27, 2015
16:23 EDTBSXBoston Scientific announces strategic collaboration with Brainlab AG
Subscribe for More Information
15:35 EDTMDTMedtronic announces consent decree with FDA for Synchromed system
Subscribe for More Information
15:31 EDTMDTFDA enters consent decree with Medtronic
The FDA announced the filing of a consent decree against Medtronic and two of the company’s officers—S. Omar Ishrak and Thomas Tefft —for repeatedly failing to correct violations, related to the manufacture of Synchromed II Implantable Infusion Pump Systems, medical devices that deliver medication to treat primary or metastatic cancer, chronic pain and severe spasticity. These violations occurred at the company’s Neuromodulation facilities in Columbia Heights, Minnesota, where the devices are manufactured. The legal action requires the company to stop manufacturing, designing and distributing new Synchromed II Implantable Infusion Pump Systems except in very limited cases, such as when a physician determines that the Synchromed II Implantable Infusion Pump System is medically necessary for a patient’s treatment. The consent decree also requires Medtronic to retain a third-party expert to help develop and submit plans to the FDA to correct violations. The consent decree will remain in effect until the FDA has determined that Medtronic has met all the provisions listed in the consent decree.
15:04 EDTBSXNotable companies reporting before tomorrow's open
Subscribe for More Information
11:02 EDTMDTMedtronic begins clinical study of Endurant Evo AAA strent graft system
Subscribe for More Information
April 23, 2015
10:00 EDTSTJOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:05 EDTSTJSt. Jude Medical price target raised to $85 from $77 at Leerink
Subscribe for More Information
06:40 EDTSTJSt. Jude Medical upgraded to Outperform from Neutral at Credit Suisse
Subscribe for More Information
April 22, 2015
08:49 EDTSTJSt. Jude Medical sees FY16 a 'strong year' for neuromodulation segment
Subscribe for More Information
08:30 EDTSTJSt. Jude Medical sees FY15 CRM constant currency sales down 2% to flat with FY14
Sees FY15 AF product sales growth of 12%-14%. Backs cardiovascular product sales growth view of 6%-8%. Sees neuromodulation products sales growth 13%-15%. Sees acquisition of spinal modulation reducing FY15 EPS by about 5c and accretive to FY16 EPS. Guidance provided during Q1 earnings conference call.
07:18 EDTSTJSt. Jude Medical sees Q2 adjusted EPS 99c-$1.01, consensus 99c
For the second quarter, St. Jude Medical expects revenue to grow in the range of 4%-5% on a constant currency basis compared to the second quarter of 2014 with currency negatively impacting second quarter revenue by approximately $125M-$135M. Revenue consensus is $1.4B.
07:18 EDTSTJSt. Jude Medical sees FY15 adjusted EPS $3.92-$3.97, consensus $3.95
Subscribe for More Information
07:16 EDTSTJSt. Jude Medical reports Q1 total CRM sales $643M, down 6% y/y
Subscribe for More Information
07:16 EDTSTJSt. Jude Medical reports Q1 adjusted EPS 93c, consensus 91c
Reports Q1 revenue $1.35B, consensus $1.32B.
April 21, 2015
15:28 EDTSTJNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's open, with earnings consensus, include Coca-Cola (KO), consensus 42c... Boeing (BA), consensus $1.81... McDonald's (MCD), consensus $1.06... EMC (EMC), consensus 36c... Abbott Laboratories (ABT), consensus 42c... Thermo Fisher Scientific (TMO), consensus $1.61... Bank of New York Mellon (BK), consensus 59c... TE Connectivity (TEL), consensus $1.01... T. Rowe Price Group (TROW), consensus $1.14... St. Jude Medical (STJ), consensus 91c... Amphenol (APH), consensus 56c... Nielsen (NLSN), consensus 47c... Citizens Financial Group (CFG), consensus 34c... Autoliv (ALV), consensus $1.31... D.R. Horton (DHI), consensus 38c... Westinghouse Air Brake Technologies (WAB), consensus 95c... Huntington Bancshares (HBAN), consensus 19c... SEI Investments (SEIC), consensus 49c... AutoNation (AN), consensus 89c... Gentex (GNTX), consensus 25c... Ryder System (R), consensus $1.00... Owens Corning (OC), consensus 13c... NuStar Energy (NS), consensus 58c... Six Flags (SIX), consensus (67c)... Tupperware Brands (TUP), consensus 98c... MarketAxess Holdings (MKTX), consensus 64c... Lithia Motors (LAD), consensus $1.22... Knight Transportation (KNX), consensus 31c... Evercore Partners (EVR), consensus 58c... Potlatch (PCH), consensus 19c... Natus Medical (BABY), consensus 29c... AZZ (AZZ), consensus 59c... United Community Banks (UCBI), consensus 29c... Sonus Networks (SONS), consensus (31c)... Angie's List (ANGI), consensus 0c... Pacific Premier Bancorp (PPBI), consensus 27c.
15:05 EDTSTJSt. Jude Medical technical comments ahead of earnings
Subscribe for More Information
11:02 EDTMDTMedtronic begins enrollment in feasibility study of Valiant Mona LSA system
Medtronic announced the start of a new feasibility study to evaluate the safety and effectiveness of the Valiant Mona LSA branch thoracic stent graft system, an investigational medical device designed to enable a completely endovascular solution for aortic aneurysms encroaching on the left subclavian artery. Cleveland Clinic cardiothoracic surgeon Dr. Eric Roselli successfully completed the first implant in the study on Thursday. He serves as the study's national primary investigator and receives consulting fees and honoraria for teaching from Medtronic. The study aims to enroll 24 subjects at up to seven sites in the United States. The purpose of the study is to characterize the safety and effectiveness of the investigational device acutely and at 30 days.
April 20, 2015
16:09 EDTBSXBoston Scientific announces long-term data underscore safety, efficacy of S-ICD
The Journal of the American College of Cardiology published data confirming the long-term safety and efficacy of the Boston Scientific S-ICD System for patients at risk of sudden cardiac arrest. The study, "Safety and Efficacy of the Totally Subcutaneous Implantable Defibrillator: 2-year Results from a Pooled Analysis of the IDE Study and EFFORTLESS Registry" was led by Dr. Martin Burke, professor of medicine at the University of Chicago. The analysis combined data from two large S-ICD studies to provide the most comprehensive look at S-ICD System patient outcomes to date. The all-cause mortality rate for the S-ICD patients was 1.6% per year, comparing favorably to observed mortality rates in similar TV-ICD studies. Currently, the S-ICD System is covered nationally by Medicare, Aetna, Cigna and others, and regionally by numerous private and Medicaid plans, providing coverage for approximately 170M individuals in the U.S. The S-ICD System has been commercially available in Europe since 2009.
09:03 EDTSTJSt. Jude Medical announces intent to acquire Spinal Modulation
Subscribe for More Information
07:44 EDTBSXSurvey shows strong momentum for Boston Scientific devices, says RBC Capital
RBC Capital says that its survey supports strong momentum for Boston Scientific's S-ICD and Watchman, and the firm thinks the company is probably gaining share in single-chamber ICDs. The firm raised its price target on the shares to $20 from $17 and recommends buying the shares at current levels or on pullbacks.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use